To study the preparation method of Schisandra total lignanoids enteric (SLE) nanoparticles and evaluate its pharmacokinetics in rats, SLE nanoparticles were prepared by modified emulsion solvent diffusion method.  The properties of SLE nanoparticles were evaluated of morphology, mean diameter and entrapment  efficiency.  An HPLC method was employed to determine the concentration of deoxyschisandrin (QS) and  schisantherrin A (SA) in plasma, which were used as an index of Schisandra total lignanoids, and the bioavailability of the nanoparticles was compared with the reference group by oral administration using SD rats.  The nanoparticles observed by transmission electronmicroscopy were round, and the mean particle sizes of SLE were (36.7 ± 4.4) nm.  Entrapment efficiency of QS and SA were (97.5 ± 0.7) % and (91.3 ± 0.8) %, respectively.  Its  pharmacokinetic process calculated with 3p97 software was fitted to a one-compartment model.  The pharmacokinetic parameters showed sustained-release property.  Compared with reference formulation, the AUCs of SLE nanoparticles were 2.3 and 5.8 times separately.  These results suggested that the incorporation into Eudragit S100 of Schisandra total lignanoids can improve the bioavailability.